Back to search

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Ruxolitinib (RUX) in combination with 5-Azacytidine (AZA) as therapy for patients with myelofibrosis (MF)DOI 10.1016/j.clml.2015.07.120
Janus activated kinase inhibition in myelofibrosis.Semantic proximity
Rationale for combination therapy in myelofibrosis.Semantic proximity
JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosisSemantic proximity
Efficacy of ruxolitinib for myelofibrosis.Semantic proximity
Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.Semantic proximity
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyureaSemantic proximity
Effects of ruxolitinib on secondary myelofibrosis following chronic neutrophilic leukemia with the CSF3R T618I mutation.Semantic proximity
Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.Semantic proximity
New nucleoside analogs for patients with hematological malignanciesSemantic proximity
Disease-modifying activity of ruxolitinib in a patient with JAK2-negative CMML-2.Semantic proximity
Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis.Semantic proximity
A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.Semantic proximity
Select a neighboring publication to make it the new centre.